GI Dynamics Announces Scientific Advisory Board Members to Further Scientific Understanding of EndoBarrier
March 12 2017 - 3:57PM
Business Wire
GI Dynamics®, Inc. (ASX:GID), a medical device company that has
commercialized EndoBarrier® in Europe, the Middle East and South
America for patients with type 2 diabetes and obesity, announced
additional members of the GI Dynamics Scientific Advisory Board
(SAB), bringing together distinguished physicians and scientists
specializing in endocrinology, gastroenterology and
bariatric/metabolic surgery. Manoel Galvao Neto, M.D., and David E.
Cummings, M.D., have joined the GI Dynamics SAB.
The GI Dynamics SAB was created to further advance the body of
evidence regarding EndoBarrier, ask and answer relevant questions
about treatment using EndoBarrier, and advance the state of patient
care with EndoBarrier. The SAB will serve as a vital resource to GI
Dynamics during its Investigational Device Exemption clinical trial
of EndoBarrier in the United States, and will support ongoing
clinical studies and commercialization in the United Kingdom,
Germany, the Middle East and select European countries.
“We are delighted to have Dr. Galvao and Dr. Cummings join the
GI Dynamics SAB,” said Scott Schorer, GI Dynamics President and
CEO. “Dr. Galvao performed the first-in-human EndoBarrier
procedures, and possesses a rich understanding of the development
history of EndoBarrier. Dr. Cummings’ is a highly analytical
endocrinologist who has a keen interest in the mechanisms of action
of type 2 diabetes and EndoBarrier.”
Dr. Galvao is a clinical associate professor at Herbert Wertheim
College of Medicine at Florida International University in Miami,
Florida, and Affiliate Professor of Surgery at ABC College of
Medicine in Canto Andrew in Sao Paulo, Brazil. Galvao will earn his
Ph.D. at the Federal University of Pernambuco, Brazil, in 2018 for
his thesis on endoscopic treatment of sleeve gastrectomy leaks.
Dr. Galvao is a board-certified specialist in digestive surgery,
gastroenterology and digestive endoscopy with a vast understanding
of bariatric endoscopy. He holds multiple positions focused on
aiding in the understanding and improvement of quality patient care
through bariatric endoscopy.
“Since my first-in-human EndoBarrier implant in 2005, I have
seen the health benefit it offers to patients in need of an
alternative treatment,” said Galvao. “I truly believe EndoBarrier
fills the existing type 2 diabetes treatment gap.”
Dr. Cummings is a Professor of Medicine in the Division of
Metabolism, Endocrinology and Nutrition at the University of
Washington, based at the Diabetes & Obesity Center of
Excellence and the V.A. Puget Sound Health Care System. He studies
the hormonal and neurochemical pathways that regulate appetite,
body weight and glucose homeostasis by using experiments ranging
from bench science to clinical investigation. A major current focus
of his research is to elucidate endocrine mechanisms that mediate
the profound effects of bariatric/metabolic surgery on diabetes and
body weight, as well as to determine the role of surgery in
diabetes care through randomized clinical trials.
Dr. Cummings is a summa cum laude graduate of Dartmouth College,
where he majored in biochemistry. He obtained his medical degree
from Harvard Medical School and the Massachusetts Institute of
Technology. He is a recipient of the Presidential Early Career
Award for Scientists and Engineers—the highest award conferred by
the US government to researchers in their early independent
careers.
“I’m very excited to join the team at GI Dynamics and help move
EndoBarrier forward,” said Cummings. “This novel device has strong
potential to recapitulate some of the magic of bariatric/metabolic
operations for type 2 diabetes and obesity without the invasiveness
of surgery.”
About GI Dynamics
GI Dynamics, Inc. (ASX:GID), is the developer of EndoBarrier,
the first endoscopically delivered device approved for the
treatment of type 2 diabetes and obesity. EndoBarrier is approved
and commercially available in multiple countries outside the United
States. EndoBarrier is not approved for sale in the United
States and is limited by federal law to investigational use only in
the United States. Founded in 2003, GI Dynamics is headquartered in
Boston, Massachusetts. For more information, please
visit www.gidynamics.com.
Forward-Looking Statements
This announcement contains forward-looking statements concerning
our development and commercialization plans, potential revenues and
revenue growth, costs, excess inventory, profitability and
financial performance, ability to obtain reimbursement for our
products, clinical trials and associated regulatory submissions and
approvals, the number and location of commercial centers offering
the EndoBarrier, and our intellectual property position. These
forward-looking statements are based on GI Dynamics’ management’s
current estimates and expectations of future events as of the date
of this announcement. Furthermore, the estimates are subject to
several risks and uncertainties that could cause actual results to
differ materially and adversely from those indicated in or implied
by such forward-looking statements. These risks and uncertainties
include but are not limited to, risks associated with the
consequences of stopping the ENDO trial and the possibility that
future clinical trials will not be successful or confirm earlier
results. Further risks are associated with obtaining funding from
third parties; the timing and costs of clinical trials; the timing
of regulatory submissions; and the timing, receipt and maintenance
of regulatory approvals. The timing and amount of other expenses
and the timing and extent of third-party reimbursement risks
associated with commercial product sales, including product
performance, competition, risks related to market acceptance of
products, intellectual-property risk; risks related to excess
inventory; and risks related to assumptions regarding the size
of the available market, the benefits of our products, product
pricing, timing of product launches, future financial results and
other factors, including those described in our filings with the
U.S. Securities and Exchange Commission. Given these uncertainties,
one should not place undue reliance on these forward-looking
statements. We do not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information or future events or otherwise, unless we are required
to do so by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170312005028/en/
Investor RelationsUnited States:For GI Dynamics,
Inc.:Monica Bellevue, 781-357-3246Investor Relations
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Apr 2023 to Apr 2024